NeuroBo appoints Marshall Woodworth as permanent CFO effective March 1, 2024

MetaVia Inc.

Marshall Woodworth, age 66, appointed CFO, Principal Financial Officer and Principal Accounting Officer.
Previously served as Acting CFO since Oct 27, 2023; engagement with WhiteCap Search terminated.
Employment agreement: 2-year initial term, $380,000 base salary, 40% target bonus, 33,496 RSUs.
Background: CFO at Nevakar, Braeburn, Aerocrine, and Furiex Pharmaceuticals (Nasdaq: FURX).
Company highlights upcoming Phase 2a data for DA-1241 (MASH) and Phase 1 start for DA-1726 (obesity).

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Marshall H. Woodworth

Chief Financial Officer

MTVA · MetaVia Inc.

Effective: 2024-03-01
Filed: March 4, 2024, 6:59 PM ET

On March 1, 2024, the Board of Directors (the “Board” ) of NeuroBo Pharmaceuticals, Inc. (the “Company” ) appointed Mr. Marshall H. Woodworth, age 66, as the Company’s Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, effective as of March 1, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Marshall H. Woodworth was appointed as Chief Financial Officer at MetaVia Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On March 1, 2024, the Board of Directors (the “Board” ) of NeuroBo Pharmaceuticals, Inc. (the “Company” ) appointed Mr. Marshall H. Woodworth, age 66, as the Company’s Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, effective as of March 1, 2024.

View on SEC.gov

MetaVia Inc. filing history →

Source: SEC EDGAR

accession 0001558370-24-002312

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.